136 related articles for article (PubMed ID: 20426518)
1. High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk ewing sarcoma patients: a long-term follow-up single-center study.
Diaz MA; Lassaletta A; Perez A; Sevilla J; Madero L; Gonzalez-Vicent M
Pediatr Hematol Oncol; 2010 May; 27(4):272-82. PubMed ID: 20426518
[TBL] [Abstract][Full Text] [Related]
2. High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients.
Molina B; Alonso L; Gonzalez-Vicent M; Andion M; Hernandez C; Lassaletta A; Cormenzana M; Lopez-Ibor B; Villa M; Molina J; Diaz MA
Pediatr Hematol Oncol; 2011 Mar; 28(2):115-23. PubMed ID: 21299340
[TBL] [Abstract][Full Text] [Related]
3. High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors.
Diaz MA; Vicent MG; Madero L
Bone Marrow Transplant; 1999 Dec; 24(11):1157-9. PubMed ID: 10642802
[TBL] [Abstract][Full Text] [Related]
4. Megachemotherapy followed by autologous stem cell transplantation in children with Ewing's sarcoma.
Drabko K; Zawitkowska-Klaczynska J; Wojcik B; Choma M; Zaucha-Prazmo A; Kowalczyk J; Gorczynska E; Toporski J; Kałwak K; Turkiewicz D; Chybicka A
Pediatr Transplant; 2005 Oct; 9(5):618-21. PubMed ID: 16176419
[TBL] [Abstract][Full Text] [Related]
5. Myeloablative chemotherapy with autologous peripheral blood stem cell transplantation in patients with poor-prognosis solid tumors - Bulgarian experience.
Avramova B; Jordanova M; Michailov G; Konstantinov D; Christosova I; Bobev D
J BUON; 2006; 11(4):433-8. PubMed ID: 17309174
[TBL] [Abstract][Full Text] [Related]
6. Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?
Al-Faris N; Al Harbi T; Goia C; Pappo A; Doyle J; Gassas A
Pediatr Blood Cancer; 2007 Aug; 49(2):190-5. PubMed ID: 17262797
[TBL] [Abstract][Full Text] [Related]
7. High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma.
Atra A; Whelan JS; Calvagna V; Shankar AG; Ashley S; Shepherd V; Souhami RL; Pinkerton CR
Bone Marrow Transplant; 1997 Nov; 20(10):843-6. PubMed ID: 9404924
[TBL] [Abstract][Full Text] [Related]
8. Autologous stem cell transplantation in acute myeloid leukemia. Factors influencing outcome. A 13 year single institution experience.
Martins C; Lacerda JF; Lourenço F; Carmo JA; Lacerda JM
Acta Med Port; 2005; 18(5):329-37. PubMed ID: 16611537
[TBL] [Abstract][Full Text] [Related]
9. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
[TBL] [Abstract][Full Text] [Related]
10. High-dose busulfan and cyclophosphamide as a conditioning regimen for autologous peripheral blood stem cell transplantation in childhood non-Hodgkin lymphoma patients: a long-term follow-up study.
Andion M; Molina B; Gonzalez-Vicent M; Alonso L; Hernandez C; Lassaletta A; Lopez-Ibor B; Villa M; Diaz MA
J Pediatr Hematol Oncol; 2011 Apr; 33(3):e89-91. PubMed ID: 21358341
[TBL] [Abstract][Full Text] [Related]
11. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
Ulrickson M; Aldridge J; Kim HT; Hochberg EP; Hammerman P; Dube C; Attar E; Ballen KK; Dey BR; McAfee SL; Spitzer TR; Chen YB
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1447-54. PubMed ID: 19822305
[TBL] [Abstract][Full Text] [Related]
12. High-dose melphalan +/- total body irradiation and autologous hematopoietic stem cell rescue for adult patients with Ewing's sarcoma or peripheral neuroectodermal tumor.
Stewart DA; Gyonyor E; Paterson AH; Arthur K; Temple W; Schachar NS; Klassen J; Brown C; Russell JA
Bone Marrow Transplant; 1996 Aug; 18(2):315-8. PubMed ID: 8864440
[TBL] [Abstract][Full Text] [Related]
13. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant.
Oberlin O; Rey A; Desfachelles AS; Philip T; Plantaz D; Schmitt C; Plouvier E; Lejars O; Rubie H; Terrier P; Michon J;
J Clin Oncol; 2006 Aug; 24(24):3997-4002. PubMed ID: 16921053
[TBL] [Abstract][Full Text] [Related]
14. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
Martino M; Console G; Irrera G; Praticò G; Stelitano C; Callea V; Morabito F; Quartarone E; Musolino C; Piro E; Brugiatelli M; Iacopino P
Am J Hematol; 2006 Dec; 81(12):973-8. PubMed ID: 16888786
[TBL] [Abstract][Full Text] [Related]
15. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
16. Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma.
Shankar AG; Ashley S; Craft AW; Pinkerton CR
Med Pediatr Oncol; 2003 Mar; 40(3):141-7. PubMed ID: 12518341
[TBL] [Abstract][Full Text] [Related]
17. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.
Blanes M; Lahuerta JJ; González JD; Ribas P; Solano C; Alegre A; Bladé J; San Miguel JF; Sanz MA; de la Rubia J
Biol Blood Marrow Transplant; 2013 Jan; 19(1):69-74. PubMed ID: 22897964
[TBL] [Abstract][Full Text] [Related]
18. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study.
Tribalto M; Amadori S; Cudillo L; Caravita T; Del Poeta G; Meloni G; Avvisati G; Petrucci MT; Pulsoni A; Leone G; Sica S; Martelli M; Tabilio A; Fioritoni G; Majolino I; Mandelli F
Haematologica; 2000 Jan; 85(1):52-8. PubMed ID: 10629592
[TBL] [Abstract][Full Text] [Related]
19. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
20. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma.
Qazilbash MH; Saliba RM; Hosing C; Mendoza F; Qureshi SR; Weber DM; Wang M; Flosser T; Couriel DR; De Lima M; Kebriaei P; Popat U; Alousi AM; Champlin RE; Giralt SA
Bone Marrow Transplant; 2007 Mar; 39(5):279-83. PubMed ID: 17262062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]